[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100535957":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":29,"responsibleParty":43,"collaborators":46,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":10,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"China Medical University Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"candidates",null,"In the first phase, patients with hepatosplenomegaly of unknown etiology will be initially screened using an electronic medical record database, and in the second phase, laboratory analysis of biomarkers, including Dry blood spot (DBS) for GBA1 enzyme activity, plasma Lyso-GB1 levels and GBA1 gene sequencing, will be performed.",{"label":13,"type":10,"description":14,"interventionNames":10},"control","Compare the blood test with the candidates group.",[16],{"name":17,"affiliation":5,"role":18},"Chung-Hsing Wang","PRINCIPAL_INVESTIGATOR",[20,25],{"name":17,"role":21,"phone":22,"phoneExt":23,"email":24},"CONTACT","0422032798","14641","005894@tool.caaumed.org.tw",{"name":26,"role":21,"phone":22,"phoneExt":27,"email":28},"Kai-Wen liu","14131","kevinagirl2@gmail.com",[30],{"facility":31,"status":10,"city":32,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"China Medical University Hospita","Taichung","Taiwan","TW",{"type":36,"coordinates":37},"Point",[38,39],120.6839,24.1469,{"lat":39,"lon":38},[42],{"name":17,"role":21,"phone":22,"phoneExt":23,"email":10},{"type":44,"investigatorFullName":17,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Attending Physicians",[47],{"name":48,"class":49},"Sanofi","INDUSTRY","100535957","screening-for-gaucher-disease-and-acid-sphingomyelinase-deficiency-100535957",false,"NCT06258577","Screening for Gaucher Disease and Acid Sphingomyelinase Deficiency","Screening for Gaucher Disease and Acid Sphingomyelinase Deficiency From Taiwanese Candidates With Splenomegaly and\u002For Thrombocytopenia","Inclusion Criteria:\n\n1. Clinical diagnosis of splenomegaly\n2. Clinical diagnosis of thrombocytopenia\n\nExclusion Criteria:\n\n1. Clinical diagnosis of gaucher disease\n2. Clinical diagnosis of acid sphingomyelinase\n3. Clinical diagnosis of malignant tumors","ALL",{"count":59,"type":60},50,"ESTIMATED","OBSERVATIONAL","High-risk screening for Gaucher disease and Acid Sphingomyelinase Deficiency in patients with splenomegaly and\u002For thrombocytopenia in Taiwan",[64],"Gaucher Disease","NOT_YET_RECRUITING","2024-04-12",{"date":68,"type":69},"2024-04-15","ACTUAL",{"date":71,"type":60},"2024-05-01",{"date":73,"type":60},"2028-12-31",{"name":17,"class":6},1]